AIM ImmunoTech (NYSEAMERICAN:AIM) Shares Down 2.7% – What’s Next?

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was down 2.7% during mid-day trading on Monday . The company traded as low as $0.2410 and last traded at $0.25. 579,959 shares traded hands during trading, a decline of 42% from the average daily volume of 1,001,889 shares. The stock had previously closed at $0.2570.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets cut their target price on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $9.00.

AIM ImmunoTech Stock Up 0.4%

The firm has a fifty day simple moving average of $0.37 and a 200-day simple moving average of $0.69. The company has a market capitalization of $3.64 million, a P/E ratio of -0.04 and a beta of 1.20. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.10.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.69) earnings per share for the quarter. The firm had revenue of $0.02 million during the quarter. On average, equities research analysts expect that AIM ImmunoTech Inc. will post -0.63 EPS for the current fiscal year.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently raised its position in AIM ImmunoTech stock. DRW Securities LLC increased its stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,545 shares of the company’s stock after acquiring an additional 26,254 shares during the period. DRW Securities LLC owned about 2.12% of AIM ImmunoTech worth $79,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.